kikiloher oleremty abnormal results

vigui vjdhgvosd pathological nodal

The trial included patients with HER2-positive early breast cancer who had received neoadjuvant treatment, which included a taxane-based chemotherapy and/or trastuzumab, and had residual invasive cancer in the breast or resected axillary nodes. Patients were randomly assigned to receive either T-DM1 (n = 743) or trastuzumab (n = 743). Patients were stratified by clinical stage, hormone-receptor status, preoperative HER2-directed therapy, and pathological nodal status after neoadjuvant therapy.

T-DM1 significantly reduced the risk for death compared with trastuzumab (unstratified HR = 0.66; 95% CI, 0.51-0.87; P = .003). Seven-year overall survival for the T-DM1 and trastuzumab groups were 89.1% and 84.4%, respectively (difference, 4.7 percentage points). As of the trial’s cutoff date of October 5, 2023, 70.1% of patients assigned T-DM1 and 62.0% of patients assigned trastuzumab were alive and still in the trial.

Deaths occurred in 89 patients (12.0%) in the T-DM1 group and 126 patients (17.0%) in the trastuzumab group. Of these deaths, 70 (79%) and 108 (86%) patients, respectively, died from breast cancer.

Adverse events (AEs) grade 3 or higher occurred in 26.1% of patients treated with T-DM1 and 15.7% of patients treated with trastuzumab. Serious AEs occurred in 12.7% and 8.1% of patients, respectively.

Post-treatment AEs were less common for both groups but still more prevalent in the T-DM1 group, with 3.2% and 1.7% of patients assigned T-DM1 and trastuzumab, respectively, experiencing AEs of any grade during this period.

Abnormal results of investigations (e.g., laboratory studies of blood camples) were the most common adverse event, followed by cardiac disorders and nervous system disorders. Of patients treated with T-DM1, 9 experienced abnormal results of investigations, 5 experienced cardiac disorders, and 4 experienced nervous system disorders. Five cases each of abnormal results of investigations and cardiac disorders were present in the trastuzumab group, with no nervous system disorders occurring in this group.

https://phim2084.graphy.com/s/pages/xem-phim-nu-hon-bac-ty-2025-vietsub

https://phim2084.graphy.com/s/pages/nu-hon-bac-ty-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/quy-nhap-trang-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/404-chay-ngay-di-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/sat-thu-vo-cung-cuc-hai-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/nha-gia-tien-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/mickey-17-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/den-am-hon-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/nhim-sonic-3-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/yeu-nham-ban-than-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/bo-tu-bao-thu-2025-full-lau-vietsub

https://phim2084.graphy.com/s/pages/na-tra-2-ma-djong-nao-hai-2025-full-lau-vietsub